Which are the top stocks recommended by Market experts today? Which are top stocks recommended By Dhwani Patel for today. Confused about your portfolio? Which stock you  should buy or sell now? Watch more on ET Now
#stockstobuy #stockstosell #etnow #stocknews  #sharemarketnews #stockmarkets #stockmarkettoday #stockinnews #stocks
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3

Subscribe Now To Our Network Channels :-
Times Now  : http://goo.gl/U9ibPb
The NewsHour Debate : http://goo.gl/LfNgFF

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

Top Stocks In Focus Today | Granules India, Birla Soft, Marksans Pharma | Dhwani Patel

Marksans Pharma Consolidated June 2023 Net Sales at Rs 500.03 crore, up 15.28% Y-o-Y

Marksans Pharma’s new tablets are similar to Advil Dual Action which is manufactured by GlaxoSmithKline Consumer Healthcare, a London-based company.

Marksans Pharma shares rally 9% on FDA nod to pain relief tablet

Shares of Tata Power will turn ex-dividend on Wednesday. The Tata group company had declared a final dividend of Rs 2 per share. The actual payment will be made on June 21.

Tata Power, Marksans Pharma, Uniparts India shares to turn ex-dividend today

Business Standard | Stocks to Watch today, June 7, 2023: Tata Power, Uniparts India, Seshasayee Paper, Marksans Pharma will turn ex-dividend on Wednesday

Stocks to Watch today | Tuesday, June 7: Adani Green, Mazagon Dock, Torrent Power | Business Standard

Marksans Pharma Consolidated March 2023 Net Sales at Rs 485.98 crore, up 16.25% Y-o-Y

With the completion of the acquisition, Marksans will start operating at the acquired facility.

Marksans Pharma completes the acquisition from Tevapharm India

Tata Elxsi’s trend is down, with supports at ₹5,790 and ₹5,630. Tata Consumer Products has a long-term bullish trend, with a range between ₹695 and ₹760. Marksans Pharma has a bullish outlook for the short- and medium-term, with supports at ₹62 and ₹57 and resistance at ₹90.

Profit Protection Strategy: Tata Elxsi and Tata Consumer Products Under the Spotlight

Broker’s Call: Marksans Pharma (Buy)

Management guided for revenue of Rs 1800 crore, gross margin of 50-51% and Ebitda margin of ~17% in FY23.

Marksans Pharma - With Focus On Backward Integration, Operating Margin Is Expected To Improve: HDFC Securities

Famotidine tablets are bioequivalent to the reference listed drug Pepcid AC tablets, a registered trademark of Johnson & Johnson Consumer Inc, which has sales of over $200 million in the US market.

Marksans Pharma climbs 2% after USFDA approval for Famotidine tablets

The creamy layer - amongst the top performing stocks

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced and in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Not a good time to consider, stock is in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.